JPW
1724

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Schwartz-Albiez, et al.	Examiner:	Unassigned
Serial No.:	10/594,382	Group Art Unit:	Unassigned
Filed:	September 26, 2006	Confirmation No:	Unassigned
International Application No.:	PCT/EP2005/003403	Docket:	294-262 PCT/US
		Dated:	January 9, 2007
International Filing Date:	March 31, 2005		
For:	METHOD FOR EXPANDING POSTEMBRYONIC STEM AND PROGENITOR CELLS FROM UMBILICAL CORD BLOOD AND IMMUNOTHERA-PEUTIC AGENT		

I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, Virginia 22313-1450
on January 9, 2007
Signature:

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicants submit herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

FOREIGN PATENT DOCUMENTS

COUNTRY	PUBLICATION NO.	PUBLICATION DATE
Germany	DE 102 45 927 A	April 15, 2004

NON-PATENT PUBLICATIONS

1. Theunissen, et al., "Long-term engrafting umbilical cord blood cells are preserved after ex vivo culture in stroma-free culture," *Online!* May 2001, http://mmserver.cjp.com/gems/blood/ABMT.10.verfaillie.pdf, pgs 599-603.

2. Pankaj, et al., "Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with o-sulfated heparin sulfates: Requirement for optimal binding interactions of heparin sulfate with early-acting cytokines and matrix proteins," *Blood* January 2000, 95(1):147-155.

3. Pankaj, et al., "Structurally specific heparin sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche," *Blood* December 1998, 92(12):4641-4651.

4. Lewis, et al., "Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact system," *Blood* June 2001, 97(11):3441-3449.

5. Schubert, "Einfluss regioselektiv modifizierter Heparansulfate auf den Erhalt and die Expansion primitiver hamatopoietischer Stammzelle and Vorlauferzellen," *Online!* 2004, http://doctor-schubert.de/downloads/Dissertation%20M.Schubert.pdf.

6. Punzel, et al., "The microenvironment of AFT024 cells maintains primitive human hematopoiesis by counteracting contact mediated inhibition of proliferation." *Cell Communication & Adhesion*, May-June 2002, 9(3):149-159.

7. Gupta, et al., "Artificial 'proteoglycan-like' molecules containing heparin sulfate enhance the ability of cytokines to maintain human hematopoietic stem cells in vitro," *Journal of Investigative Medicine*, 1995, 43(SUPL.2):342A.

8. Moore, et al., "In vitro maintenance of highly purified, transplantable hematopoietic stem cells," *Blood*, 1997, 89(12):4337-4347.

9. Moore, et al., "Hematopoietic Activity of a Stromal Cell Transmembrane Protein Containing Epidermal Growth Factor-Like Repeat Motifs," *Proceedings of the National Academy of Sciences of USA,* April 1997, 94:4011-4016.

10. Stringer, et al., "Identification of an MIP-1alpha-binding heparin sulfate oligosaccharide that supports long-term in vitro maintenance of human LTC-ICs," *Blood*, March 2003, 101(6):2243-2245.

Each of the above references were listed in the International Search Report issued in the corresponding International Application. A copy of the International Search Report was previously filled with the application.

Copies of the cited references should have been provided by the International Searching Authority. Upon receipt of a Notification of Acceptance of Application indicating what items have been received by the Patent and Trademark Office, Applicant will review the same to ensure that the references were provided.

The references are listed on Applicant's Form PTO-1449, which is attached to this Information Disclosure Statement for the convenience of the Examiner. Applicant requests consideration of each of the documents listed on the attached Form PTO-1449, and that such consideration be indicated by initialing each citation thereon.

This Statement is being filed before the mailing of a first Office Action on the merits. Applicant believes that no fee for this submission is due. If, however, a fee is due for entry of this Information Disclosure Statement, the Office is authorized to charge Deposit Account No. 08-2461 for any such fee.

If there are any questions regarding this submission, please contact Applicant's attorney at the phone number listed below.

Respectfully submitted,



Edna I. Gergel, Ph.D.
Registration No.: 50,819
Patent Agent for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791-4407
(516) 822-3550
EIG/sbs

231529_1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 294-262 PCT/US	SERIAL NO. 10/594,382
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Schwartz-Albiez, et al.	CONFIRMATION NO. Unassigned
(Use several sheets if necessary)	FILING DATE September 26, 2006	GROUP Unassigned

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES	TRANSLATION NO
		DE 102 45 927 A	04/15/2004	Germany				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			Theunissen, et al., "Long-term engrafting umbilical cord blood cells are preserved after ex vivo culture in stroma-free culture," *Online!* May 2001, http://mmserver.cjp.com/ gems/blood/ABMT.10.verfaillie.pdf, pgs 599-603.
			Pankaj, et al., "Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with o-sulfated heparin sulfates: Requirement for optimal binding interactions of heparin sulfate with early-acting cytokines and matrix proteins," *Blood* January 2000, 95(1):147-155.
			Pankaj, et al., "Structurally specific heparin sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche," *Blood* December 1998, 92(12):4641-4651.
			Lewis, et al., "Umbilical cord blood cells capable of engrafting in primary, secondary, and tertiary xenogeneic hosts are preserved after ex vivo culture in a noncontact system," *Blood* June 2001, 97(11):3441-3449.
			Schubert, "Einfluss regioselektiv modifizierter Heparansulfate auf den Erhalt and die Expansion primitiver hamatopoietischer Stammzelle and Vorlauferzellen," *Online!* 2004, http://doctor-schubert.de/downloads/Dissertation%20M.Schubert.pdf.

EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 294-262 PCT/US	SERIAL NO. 10/594,382
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Schwartz-Albiez, et al.	CONFIRMATION NO. Unassigned
(Use several sheets if necessary)	FILING DATE September 26, 2006	GROUP Unassigned

			Punzel, et al., "The microenvironment of AFT024 cells maintains primitive human hematopoiesis by counteracting contact mediated inhibition of proliferation." *Cell Communication & Adhesion*, May-June 2002, 9(3):149-159.
			Gupta, et al., "Artificial 'proteoglycan-like' molecules containing heparin sulfate enhance the ability of cytokines to maintain human hematopoietic stem cells in vitro," *Journal of Investigative Medicine*, 1995, 43(SUPPL2):342A.
			Moore, et al., "In vitro maintenance of highly purified, transplantable hematopoietic stem cells," *Blood*, 1997, 89(12):4337-4347.
			Moore, et al., "Hematopoietic Activity of a Stromal Cell Transmembrane Protein Containing Epidermal Growth Factor-Like Repeat Motifs," *Proceedings of the National Academy of Sciences of USA*, April 1997, 94:4011-4016.
			Stringer, et al., "Identification of an MIP-1alpha-binding heparin sulfate oligosaccharide that supports long-term in vitro maintenance of human LTC-ICs," *Blood*, March 2003, 101(6):2243-2245.

231578_1

EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.